Last update 20 Mar 2025

Mitoxantrone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DAD, Mintoxantrone Hydrochloride and Glucose, Mitoxant
+ [16]
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Canada (31 Dec 1984)
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H30Cl2N4O6
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N
CAS Registry70476-82-3

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally advanced breast cancer
Australia
24 Jan 2001
Myeloid Leukemia
Australia
24 Jan 2001
Non-Hodgkin Lymphoma
Australia
24 Jan 2001
Cancer Pain
United States
13 Oct 2000
Multiple Sclerosis, Relapsing-Remitting
United States
13 Oct 2000
Castration-Resistant Prostatic Cancer
United States
13 Nov 1996
Acute Myeloid Leukemia
United States
13 Nov 1996
Hepatocellular Carcinoma
Japan
01 Jun 1989
Metastatic breast cancer
United States
23 Dec 1987
Leukemia
Japan
02 Oct 1987
Lymphoma
Japan
02 Oct 1987
Breast Cancer
Japan
02 Oct 1987
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Gastric AdenocarcinomaPhase 3
China
05 Jul 2023
Locally Advanced Gastric AdenocarcinomaPhase 3
China
05 Jul 2023
stomach adenocarcinomaPhase 3
China
05 Jul 2023
stomach adenocarcinomaPhase 3
China
05 Jul 2023
Invasive Mammary CarcinomaPhase 3
China
11 Dec 2019
Invasive Mammary CarcinomaPhase 3
China
11 Dec 2019
Thyroid CancerPhase 3
China
07 Nov 2017
Thyroid CancerPhase 3
China
07 Nov 2017
Indolent Non-Hodgkin LymphomaPhase 3
United States
16 Mar 1998
Adult Lymphoblastic LymphomaPhase 2
United States
01 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
rmkqrsgvsb(jovmnfmopt) = fnmosihklb duezlqgkyt (zdtxkukbju )
Positive
14 May 2024
Not Applicable
30
BUCY+M regimen
uwolnrgkef(qnjoenyuwh) = fbnzpezjzk bjwzgqfdos (rtlnbicmtr )
Positive
14 May 2024
FBC+M regimen
uwolnrgkef(qnjoenyuwh) = yrwfnzwast bjwzgqfdos (rtlnbicmtr )
Not Applicable
Acute Myeloid Leukemia
CEBPA | NPM1 | IDHI ...
16
Lipo-MIT combined with CLAG regimen
ruwmzpefvi(rserjeadmt) = exoasuwwza xvfzbiefka (exgdijqhfe, 36.05% - 80.88)
Positive
14 May 2024
Not Applicable
12
Combination therapy based on Lipo-MIT
ocugdretsj(nbgmtotgma) = whfsbeukjr lwlkgsvtzn (lgotmvwssa )
Positive
14 May 2024
Not Applicable
Extranodal NK-T-Cell Lymphoma
HLH | circulating tumor DNA
5
P-GEMD regimen
cnsxniytlk(gniakzyekh) = ukaybulmem brmpgfossy (hdvtuxzfxw )
Positive
09 Jun 2023
Phase 1/2
50
glucocorticoids+hydroxyurea+vincristine
onmivwjxme = nakwbgkavv ncwxprcvrd (hldgtikepd, zqrjpxfqgb - gbjvococqh)
-
07 Jun 2023
Not Applicable
82
iziogaswfs(zisgvfurnu) = 73.2% szmohxvoyl (fbpuedpyfm )
Positive
31 May 2023
Phase 1
10
Alvocidib + Cytarabine/Mitoxantrone
fzjhgdgolp(biwukkpxgr) = diarrhea was the most frequent (100%) suidwltcvg (jebnpvqarw )
-
11 Jun 2022
Alvocidib + Cytarabine/Daunorubicin
Phase 2
49
pxypjjyavy = vbwdibjoea xgdblpnhgf (wramxtntse, gyxuwkqtzf - toejsocuea)
-
22 Apr 2022
Phase 3
381
alzcxgyzsz(hhthubzvyi) = All adverse events recovered within one month after intervention rlymhsbgyq (uzfqsxcpbv )
Positive
15 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free